descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 1983 English Publisher:Elsevier BVJournal:Progress in Neuro-Psychopharmacology and Biological Psychiatry, volume 7, pages 89-IN6 (issn: 0278-5846,

Authors: Brij B. Sethi; Sanjay Dube;

doi: 10.1016/0278-5846(83)90093-3

pmid: 6682990

Propranolol in schizophrenia

- Summary
- Subjects
- Metrics

Abstract

1. 15 schizophrenic patients diagnosed according to criteria of I.C.D.-9 were treated with d1-propranolol in a 4 week open study. 2. A fixed dose schedule was followed and a maximum dose of 1920 mg/day was reached by day 17. 3. Results revealed a significant reduction in core schizophrenic symptoms of CPRS & BPRS starting between 1st and second weeks of therapy. Higher doses were well tolerated and serious bradycardia occurred only in 3 patients. 4. The implications of these results are discussed.

Keywords

Adult, Male, Psychiatric Status Rating Scales, Schizophrenia, Humans, Schizophrenic Psychology, Propranolol

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	8
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average